Compare Revvity Inc (RVTY) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Standard Lithium Ltd — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Standard Lithium Ltd trades at $1.59 (market cap $398.07M). The key difference: Revvity Inc is far larger — about 42.7× Standard Lithium Ltd's market cap, and Revvity Inc pays a 0.18% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Standard Lithium Ltd for 23 Days on average.
| RVTY | SLI | |
|---|---|---|
Market Cap | $16.98B | $398.07M |
Volume | 1,456,900 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $157.36 | $5.65 |
52-Week Low | $82.26 | $1.61 |
Typical Hold Time | 12 Days | 23 Days |
Enterprise Value | $19.30B | $260.98M |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
SLI trades at $1.625, down 1.52% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has beaten EPS estimates in recent quarters. Key developments include progress toward a 2026 final investment decision for its Arkansas lithium project and new offtake agreements.
SLI presents high risk with no current revenue and negative cash flow from operations, but significant upside potential exists if its lithium projects advance. The consensus price target of $3.83 implies 136% upside, supported by 100% buy ratings from analysts. Execution risk on project timelines and funding remains the primary concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
